Pinealon: A Pineal-Derived Tripeptide for Cognitive and Neuroprotective Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to Pinealon. Pinealon is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

In the 1970s, a Soviet research program set out to determine whether short peptide fragments extracted from animal glands could extend lifespan by restoring tissue-specific gene expression. Fifty years later, that program has generated hundreds of publications, a small industry of Russian-marketed "cytogen" supplements, and a body of English-language scientific literature that is difficult to assess without knowing where most of it came from. Pinealon is one of the compounds at the center of that story.

This article covers what Pinealon is, how the Khavinson group proposes it works, what the published evidence actually shows, and where the limitations of that evidence begin.

Key Takeaways

• Regulatory Status: Not FDA-approved for human use; no regulatory classification as a bulk drug substance for U.S. compounding; sold as a "cytogen" supplement in Russia and through gray-market online vendors. As of April 2026, it is not available through licensed U.S. providers.
• Research Stage: Preclinical only in peer-reviewed English-language literature; no completed randomized controlled trials in humans as of April 2026.
• Availability: Not legally marketed for human use in the United States. Superpower does not offer this substance.
• Compound reference data: Pinealon (EDR) on PubChem (CID 71462546)
• What it is: A synthetic tripeptide (glutamate-aspartate-arginine, or EDR) developed by Vladimir Khavinson's group and proposed to influence gene expression in pineal and brain tissue.
• What the evidence actually shows: In vitro and rodent preclinical data suggesting antioxidant, neuroprotective, and cell-viability effects; no completed human efficacy trials as of April 2026.

Where Pinealon Comes From and How It Works

Origin and the Khavinson bioregulator concept

Pinealon is a synthetic tripeptide with the amino acid sequence glutamate-aspartate-arginine (abbreviated EDR), developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The compound belongs to a family of short peptides Khavinson's group terms "cytomedins" or "bioregulators," the central hypothesis of which is described in a 2010 review by Anisimov and Khavinson published in Biogerontology. That review, summarizing more than three decades of the St. Petersburg program's work, proposes that tissue-specific short peptides isolated or synthesized from glandular sources can regulate gene expression, extend lifespan in rodents, and suppress tumorigenesis. Pinealon is the synthetic analog designed to target pineal gland and brain cortex tissue.

The Khavinson bioregulator hypothesis remains outside mainstream Western pharmacology. The evidence base reviewed in that 2010 paper, including the life-extension and anti-tumor claims, originates almost entirely from a single research lineage. Independent replication by Western groups is essentially absent from the peer-reviewed literature.

Proposed mechanism: gene expression and DNA binding

The primary mechanistic hypothesis advanced by the Khavinson group is that short peptides like EDR (Pinealon) interact directly with DNA promoter regions, complementarily binding to regulatory sequences and modulating transcription. A 2021 systematic review by Khavinson, Popovich, and Linkova published in Molecules presents this framework, proposing that tripeptides including EDR act as transcription modulators through sequence-specific DNA binding. A 2016 paper by Khavinson, Linkova, Tarnovskaya, and colleagues in Bulletin of Experimental Biology and Medicine extended that hypothesis with computational-docking data for short bioregulatory peptides binding candidate promoter sequences, an incremental mechanistic argument that illustrates how tightly the evidence base clusters around the originating group. Biophysical support for the DNA-interaction claim comes from a 2019 study by Silanteva, Komolkin, and colleagues published in Journal of Physical Chemistry B, which characterized the interactions of Glu-Asp-Arg with DNA in the presence of mono- and divalent ions at the molecular level. A 2011 study by Fedoreyeva, Kireev, Khavinson, and colleagues published in Biochemistry (Moscow) used fluorescence-labeled EDR and the related tetrapeptide AEDG to show that these tripeptides penetrate HeLa cell nuclei and bind specific DNA sequences in vitro — one of the few papers using independent methodology to support the nuclear-uptake claim.

A parallel mechanism claim involves serotonin pathway modulation. A 2014 study by Khavinson, Linkova, Tarnovskaya, and colleagues published in Bulletin of Experimental Biology and Medicine reported that short peptides including EDR increase serotonin expression in brain cortex cells in vitro. This finding is frequently cited as mechanistic support for cognitive and mood-related effects, though the evidence remains in vitro only.

A 2022 review by Ilina, Khavinson, Linkova, and colleagues published in International Journal of Molecular Sciences extended the gene-expression model to propose neuroepigenetic mechanisms for ultrashort peptides including EDR in the context of Alzheimer's disease pathogenesis. A companion 2020 review by Khavinson, Linkova, Kozhevnikova, and colleagues in Molecules similarly proposed that EDR regulates gene expression and protein synthesis relevant to Alzheimer's disease pathogenesis; the "possible mechanism" phrasing in the title is honest about the speculative status. This framework should be understood as a hypothesis from the originating group. It has biophysical support at the molecular level but remains contested outside that laboratory network.

Oxidative stress and cell viability: the in vitro evidence

A key Pinealon-specific primary data paper is a 2011 in vitro study in Rejuvenation Research by Khavinson, Ribakova, Kulebiakin, and colleagues. Using cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells exposed to receptor-dependent and receptor-independent oxidative stress, the authors reported that Pinealon (Glu-Asp-Arg) produced dose-dependent restriction of reactive oxygen species accumulation, decreased propidium-iodide-positive necrotic cell death, and induced delayed ERK 1/2 activation with cell-cycle modification; the antioxidant and cytoprotective effects saturated at lower concentrations while cell-cycle effects continued at higher concentrations, which the authors used to argue for a direct genomic interaction beyond antioxidant activity. These findings represent one of the few English-language primary-experimental citations specific to EDR, and they underpin the antioxidant and neuroprotective framing that appears throughout the subsequent literature. Earlier companion papers in Uspekhi Gerontologii in 2008 provide the foundational oxidative-stress and antihypoxic data that later studies reference. Kozina, Arutiunian, Stvolinskiy, and colleagues published an in vitro bioactivity screen of regulatory peptides including Pinealon from the Arutjunyan lab, and a companion paper by Kozina characterized antihypoxic properties of short peptides including Pinealon in rodent hypoxia models. Both are Russian-language originals and carry the peer-review limitations of that venue, so they should be read as documenting the evidence base rather than as standalone proof of clinical benefit.

What the Animal Research Shows

Rodent ischemia and neuroprotection models

The most substantive in vivo Pinealon data comes from a series of rodent papers by Mendzheritsky, Karantysh, and colleagues at an affiliated Russian research group. A 2011 study in Uspekhi Gerontologii used a rat carotid-artery-occlusion model and reported that Pinealon pretreatment modulates behavior and caspase-3 activity — a marker of apoptosis — following ischemic challenge. Follow-up work from the same group extended that profile into hypoxia and hypothermia paradigms. A 2014 paper by Mendzheritskiĭ, Karantysh, Ryzhak, and colleagues examined Pinealon combined with Cortexin and reported effects on serum cytokines and brain caspase-3 activity, and a 2015 study by the same group characterized behavior and neurochemistry of Pinealon and Cortexin in 18-month-old rats under hypoxia and hypothermia. These papers document the preclinical evidence base. They are not sufficient to establish clinical neuroprotection in humans: sample sizes were small, the models involved extreme ischemic or hypoxic challenge conditions, and all studies originate from affiliated Russian laboratories without independent replication.

Alzheimer's disease preclinical models

The most recent and clinically relevant preclinical work involves Alzheimer's disease models. A 2017 study by Kraskovskaya, Kukanova, Linkova, and colleagues published in Bulletin of Experimental Biology and Medicine provided in vitro evidence that EDR and related tripeptides restore neuronal spine density in Alzheimer's-model preparations, a finding extended in a 2021 mouse model study by Khavinson, Ilina, Kraskovskaya, and colleagues published in Pharmaceuticals. That 2021 paper reported that EDR and KED tripeptides preserve dendritic spines and neuroplasticity markers in a mouse model of Alzheimer's disease. This is the strongest recent Pinealon preclinical paper, but the absence of any human Alzheimer's data makes extrapolation premature. A 2024 study by Kraskovskaya, Linkova, Sakhenberg, and colleagues published in International Journal of Molecular Sciences represents the most recent primary-experimental citation, reporting that short peptides including EDR protect fibroblast-derived induced neurons from age-related changes. All of these papers come from the same research network.

Prenatal oxidative stress model

A 2012 preclinical rat study by Arutjunyan, Kozina, Stvolinskiy, and colleagues published in International Journal of Clinical and Experimental Medicine reported that maternal Pinealon administration protected offspring against prenatal hyperhomocysteinemia-induced neurodevelopmental damage. This study is cited in the Khavinson literature to support oxidative-stress and neuroprotection claims. It is a single-lab, small-sample animal model and should be understood as a mechanistic signal, not clinical evidence.

What the Human Evidence Looks Like

No completed RCTs as of April 2026

As of April 2026, a PubMed search for "Pinealon human" and "EDR peptide clinical trial" returns no completed, peer-reviewed randomized controlled trials. The preclinical literature is almost entirely rodent and in vitro. No Phase 1 safety study of Pinealon has been published in English-language indexed journals. No Phase 2 or Phase 3 efficacy trial exists in any population. The Russian clinical claims made for cytomedins as a class — summarized in the Anisimov-Khavinson 2010 Biogerontology review — are primarily observational or open-label, conducted within the St. Petersburg program, and have not been subjected to independent peer review in Western journals.

What single-lab dominance means for evidence quality

Virtually all published Pinealon research originates from Vladimir Khavinson's Institute of Bioregulation and Gerontology and closely affiliated Russian laboratories, including the Mendzheritsky group, the Chalisova/Voicekhovskaya group, the Arutjunyan/Kozina group, and the Linkova/Kraskovskaya group. A 2011 tissue-culture study by Khavinson, Linkova, Chalisova, and colleagues in Bulletin of Experimental Biology and Medicine on pineal cell organotypic culture responses to short peptides is representative of the methodology that dominates this literature, and a 2012 Chalisova-lab experiment by Voicekhovskaya, Chalisova, Kontsevaya, and colleagues extended that approach by showing that bioregulatory tripeptides differentially affected proliferation in skin cells from young versus old rats, a finding the group uses to support the "age-dependent response" framing. When a compound's entire evidence base clusters around a single research lineage with no independent replication, the appropriate epistemic response is to treat reported findings as hypothesis-generating rather than confirmatory. That is the status of Pinealon's evidence base today.

Pinealon vs. Epitalon: Key Differences in the Khavinson Series

Pinealon and Epitalon are the two most widely discussed compounds in the Khavinson bioregulator series. Both are short synthetic peptides derived from pineal gland research by the same group. They differ in sequence, proposed target, and evidence focus. Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly, AEDG) developed as a synthetic analog of epithalamin — a natural pineal gland extract — and the Khavinson group has primarily investigated it for telomerase activation and lifespan extension. Pinealon is a tripeptide (Glu-Asp-Arg, EDR) that the group targets toward cortical and pineal gene expression, with its published evidence focused on oxidative stress, neuronal viability, and Alzheimer's-related preclinical models.

The distinction matters because consumers and researchers sometimes use the names interchangeably or assume that evidence for one compound transfers to the other. The mechanisms proposed, the receptor or genomic targets hypothesized, and the specific preclinical models used differ between the two. This comparison is for scientific context only. Both compounds share the same fundamental evidence limitations: single-lab origin, preclinical-only human-relevant data, and no completed Western RCTs. Neither is FDA-approved or legally marketed for human use in the United States.

Regulatory and Legal Status

FDA classification

As of April 2026, Pinealon has no FDA-approved indication for any human use and no established regulatory classification as a bulk drug substance under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. It is not on the FDA's Category 1 (permissible for compounding) bulk drug substance list and has not been evaluated in the FDA's bulk drug substance nomination process in a way that would permit its use in U.S. compounded medications. It is not available through licensed U.S. compounding pharmacies by prescription.

What this means practically

Products labeled as "Pinealon" sold through online vendors — typically marketed as "research use only" or as Russian cytogen supplements — are not regulated by the FDA. There is no legal pathway to obtain pharmaceutical-grade Pinealon for human use in the United States through licensed medical channels. Independent testing of peptide products sold through gray-market vendors has documented contamination, incorrect amino acid sequences, incorrect concentrations, and misidentified compounds. The absence of any completed Phase 1 human safety study means the side effect profile in humans is unknown, and dosing information that circulates online has no clinical trial basis.

Safety: What Is and Is Not Known

Absence of clinical safety data

No Phase 1 safety study of Pinealon in humans has been published in indexed, English-language peer-reviewed literature. There is no established human pharmacokinetic profile for Pinealon: absorption, distribution, metabolism, and excretion have not been characterized in humans. What exists in vitro and in animal models is a profile suggesting low acute toxicity and antioxidant activity, but this does not constitute a human safety assessment. The side effect profile in humans is unknown.

Risks from unregulated sources

Because Pinealon is not legally marketed in the United States, any product obtained online exists outside pharmaceutical-grade manufacturing standards. The risks are not theoretical: a 2015 analytical study in Talanta by Vanhee, Janvier, and colleagues at the Belgian Official Medicines Control Laboratory applied a validated LC-MS/MS screening method to illegal and counterfeit injectable peptide preparations referred by customs and the Belgian Federal Agency for Medicines and Health Products, framing counterfeit peptide supply as a documented public health concern with identity and purity problems across seized samples. There is no way for a consumer to verify the identity, purity, or concentration of any product purchased through gray-market channels. This is a material risk that exists independently of any questions about Pinealon's proposed biological activity.

Who Should Not Use Pinealon

Based on Pinealon's proposed mechanisms, the following groups face elevated theoretical risk. This is not an exhaustive clinical assessment. No human safety data exists to formally characterize contraindications.

• Individuals with active or suspected neurological malignancy: Pinealon's proposed effects on neuronal proliferation and cell viability could theoretically affect tumor cell behavior, though this has not been studied.
• Pregnant or breastfeeding individuals: No safety data exists for these populations in any species relevant to human developmental biology.
• Individuals taking medications that affect serotonin signaling: The proposed serotonin-expression modulating effect creates a theoretical interaction concern, though no pharmacokinetic or pharmacodynamic interaction data exists.
• Individuals with autoimmune neurological conditions: The absence of immunological safety data makes this population particularly unsuitable for an unregulated, unstudied compound.
• Competitive athletes: Pinealon, as a non-approved substance with no established therapeutic indication, falls under the S0 (Non-Approved Substances) category of the 2026 WADA Prohibited List, which prohibits any pharmacological substance not approved by a regulatory authority for human therapeutic use.

Which Biomarkers Are Relevant if You Are Exploring Peptide Science?

Understanding your biological baseline is a reasonable step before exploring any area of emerging research. Several measurable markers connect directly to the mechanisms Pinealon's preclinical research has focused on: oxidative stress, neuroinflammation, and metabolic context for cognitive aging.

• High-sensitivity C-reactive protein (hs-CRP): A systemic marker of inflammatory activity. Relevant because the Khavinson group's neuroprotection claims center on oxidative and inflammatory burden in brain tissue. Baseline hs-CRP provides an objective measure of the inflammatory context that compounds like Pinealon are hypothesized to address. A 2023 systematic review and meta-analysis in Journal of Clinical Neuroscience by Long, Chen, and colleagues pooled 13 articles covering 14 cohort studies and reported that high peripheral CRP was associated with an increased risk of conversion from normal cognition to dementia (HR 1.473, 95% CI 1.037–2.090, p = 0.039), though the same analysis did not find CRP predictive of general future cognitive decline — an important limitation when interpreting hs-CRP as a cognitive risk marker.
• Homocysteine: A neurotoxic amino acid whose elevation is linked to oxidative damage in neural tissue. A 2006 mechanistic review in FEBS Letters by Obeid and Herrmann summarized how mild-to-moderate hyperhomocysteinemia promotes disturbed methylation and redox potentials, calcium influx, amyloid and tau accumulation, apoptosis, and neuronal death — effects the authors noted can be partially blocked by folate, NMDA-receptor antagonists, or antioxidants, though this is a narrative mechanistic review, not an interventional human trial. The Arutjunyan group's rat model specifically used hyperhomocysteinemia as the oxidative insult against which Pinealon was tested. Tracking homocysteine provides direct biological context for the oxidative-stress mechanism the preclinical literature invokes.
• Insulin-like Growth Factor 1 (IGF-1): A systemic growth and neuroprotective signaling marker. IGF-1 declines with age and is mechanistically connected to neuronal survival pathways. Because Pinealon's claimed effects include modulation of neuroplasticity-related gene expression, the broader neuroprotective signaling environment — of which IGF-1 is a measurable component — is relevant baseline context.
• Glucose and HbA1c: Metabolic dysregulation accelerates neuroinflammation and is a documented risk factor for cognitive decline. Blood glucose and HbA1c establish the metabolic baseline for anyone evaluating cognitive aging compounds.
• Comprehensive metabolic panel (liver and kidney function): Any investigational compound introduces a theoretical hepatic or renal burden. Baseline organ function markers establish a reference point for anyone considering compounds without established human pharmacokinetic data.

When to Take This Seriously

If cognitive decline, memory concerns, or neurological aging are driving interest in Pinealon, those are real concerns with well-established clinical pathways. A neurologist or geriatric medicine specialist can evaluate cognitive changes systematically. Established risk-factor modification — optimizing neurotransmitter and cognitive longevity biomarkers and addressing modifiable contributors like inflammation, homocysteine elevation, and metabolic dysfunction — has a far stronger evidence base than any unregulated peptide. Understanding where your biomarkers stand is the actionable first step, not a compound with no human trial data.

For those interested in the biology of cellular aging and longevity, the overlap with Pinealon's proposed mechanisms is real: oxidative stress, neuroinflammation, and gene expression regulation are active areas in aging research. But the most defensible version of that interest starts with objective measurement. That is the foundation of Superpower's approach to preventive health: understanding your biology with precision before making any clinical decision.

IMPORTANT SAFETY INFORMATION

Pinealon (EDR; glutamate-aspartate-arginine) is not FDA-approved for any human therapeutic indication. Superpower Health does not prescribe, sell, compound, or facilitate access to Pinealon. Superpower is a technology platform; Superpower does not prescribe or dispense medications.

Pinealon has no established regulatory pathway for human use in the United States. It is not permissible for use in compounded medications under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Products sold online as "research use only" are not subject to FDA manufacturing oversight or quality standards.

No Phase 1 human safety study has been published. The human side effect profile, pharmacokinetic profile, and drug interaction potential are unknown. Do not use this compound without fully informed provider supervision, which is not legally available in the United States.

Theoretical contraindications based on proposed mechanism: active or suspected neurological malignancy; pregnancy or breastfeeding; concurrent use of serotonergic medications; autoimmune neurological conditions. This is not an exhaustive list.

Warnings: contamination risk and dosing inconsistency from unregulated gray-market sources; absence of human pharmacokinetic data; unknown long-term safety; no established therapeutic dose; no independent replication of preclinical findings outside the originating research group.

As of the 2026 WADA Prohibited List, Pinealon is prohibited under S0 (Non-Approved Substances) for competitive athletes.

This is not a complete list of risks. No FDA-approved prescribing information exists for Pinealon.

Additional Questions

Is Pinealon safe for human use?

Unknown. No Phase 1 human safety study has been published for Pinealon. The human pharmacokinetic profile, side effect profile, and drug interaction potential are all uncharacterized. Products obtained through gray-market vendors carry additional contamination and dosing-inconsistency risks that are entirely separate from the compound's proposed biological activity.

What is the Khavinson bioregulator theory?

Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology proposes that short peptides (two to four amino acids) derived from specific tissues can bind DNA promoter regions and restore tissue-specific gene expression patterns that decline with aging. The theory is detailed in a foundational 2010 review by Anisimov and Khavinson in Biogerontology. The hypothesis has biophysical support at the molecular level but has not achieved mainstream acceptance in Western pharmacology, in part because the evidence base remains concentrated within a single research institution.

Are peptides like Pinealon legal again after 2026?

The February 2026 FDA reclassification primarily affected GH secretagogues and other compounds that had been nominated for Category 1 bulk drug substance status. Pinealon was not affected by this reclassification because it was never in the U.S. compounding pipeline. Its legal status as of April 2026 remains unchanged: not approved, not permissible for compounding, not legally marketed for human use.